Cholangitis

Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…

Genetic variations that predispose people toward developing primary sclerosing cholangitis (PSC) are significantly associated with a higher risk of ulcerative colitis, a primary type…

High levels of CCL24, the protein targeted by Chemomab Therapeutics’ investigational antibody-based therapy CM-101, are associated with biological pathways contributing to the progression of…

Daily treatment with Mirum Pharmaceuticals’ oral candidate volixibat significantly reduced itching — medically known as pruritus — and fatigue for adults with primary…

Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).

The first patient has been enrolled in WIND-PSC, a global study to track the natural course of primary sclerosing cholangitis (PSC) and generate real-world…

Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…

One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…

Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with itch, or pruritus, due to…